|
1
|
Shimada H, Ochiai T and Nomura F: Japan
p53 Antibody Research Group: Titration of serum p53 antibodies in
1,085 patients with various types of malignant tumors: A
multiinstitutional analysis by the Japan p53 Antibody Research
Group. Cancer. 97:682–689. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shimada H, Takeda A, Arima M, Okazumi S,
Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, et
al: Serum p53 antibody is a useful tumor marker in superficial
esophageal squamous cell carcinoma. Cancer. 89:1677–1683. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamamoto S, Chishima T, Adachi S, Harada
F, Toda Y, Arioka H, Hasegawa N and Kakuta Y: Serum p53 antibody in
breast cancer. Cancer Biomark. 14:203–206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamaguchi T, Takii Y and Maruyama S:
Usefulness of serum p53 antibody measurement in colorectal cancer:
An examination of 1384 primary colorectal cancer patients. Surg
Today. 44:1529–1535. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ochiai H, Ohishi T, Osumi K, Tokuyama J,
Urakami H, Seki S, Shimada A, Matsui A, Isobe Y, Murata Y, et al:
Reevaluation of serum p53 antibody as a tumor marker in colorectal
cancer patients. Surg Today. 42:164–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang SC, Lin JK, Lin TC and Liang WY:
Genetic alteration of p53, but not overexpression of intratumoral
p53 protein, or serum p53 antibody is a prognostic factor in
sporadic colorectal adenocarcinoma. Int J Oncol. 26:65–75.
2005.PubMed/NCBI
|
|
7
|
Tang R, Ko MC, Wang JY, Changchien CR,
Chen HH, Chen JS, Hsu KC, Chiang JM and Hsieh LL: Humoral response
to p53 in human colorectal tumors: A prospective study of 1,209
patients. Int J Cancer. 94:859–863. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shiota G, Ishida M, Noguchi N, Oyama K,
Takano Y, Okubo M, Katayama S, Tomie Y, Harada K, Hori K, et al:
Circulating p53 antibody in patients with colorectal cancer:
Relation to clinicopathologic features and survival. Dig Dis Sci.
45:122–128. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Noaki R, Kawahara H, Watanabe K, Ushigome
T, Kobayashi S and Yanaga K: Serum p53 antibody is a useful tumor
marker of early colorectal cancer. Int Surg. 95:287–292.
2010.PubMed/NCBI
|
|
10
|
Suppiah A, Alabi A, Madden L, Hartley JE,
Monson JR and Greenman J: Anti-p53 autoantibody in colorectal
cancer: Prognostic significance in long-term follow-up. Int J
Colorectal Dis. 23:595–600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. (7th edition).
2010.
|
|
12
|
Takeda A, Shimada H, Nakajima K, Yoshimura
S, Suzuki T, Asano T, Ochiai T and Isono K: Serum p53 antibody as a
useful marker for monitoring of treatment of superficial colorectal
adenocarcinoma after endoscopic resection. Int J Clin Oncol.
6:45–49. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Joypaul BV, Newman EL, Hopwood D, Grant A,
Qureshi S, Lane DP and Cuschieri A: Expression of p53 protein in
normal, dysplastic and malignant gastric mucosa: An
immunohistochemical study. J Pathol. 170:279–283. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bennett WP, Colby TV, Travis WD, Borkowski
A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, et
al: p53 protein accumulates frequently in early bronchial
neoplasia. Cancer Res. 53:4817–4822. 1993.PubMed/NCBI
|
|
15
|
Morell A, Terry WD and Waldmann TA:
Metabolic properties of IgG subclasses in man. J Clin Invest.
49:673–680. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ito K, Hibi K, Ando H, Hidemura K,
Yamazaki T, Akiyama S and Nakao A: Usefulness of analytical CEA
doubling time and half-life time for overlooked synchronous
metastases in colorectal carcinoma. Jpn J Clin Oncol. 32:54–58.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Choi JS and Min JS: Significance of
postoperative serum level of carcinoembryonic antigen (CEA) and
actual half life of CEA in colorectal cancer patients. Yonsei Med
J. 38:1–7. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takeda A, Shimada H, Nakajima K, Imaseki
H, Suzuki T, Asano T, Ochiai T and Isono K: Monitoring of p53
autoantibodies after resection of colorectal cancer: Relationship
to operative curability. Eur J Surg. 167:50–53. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawahara H, Watanabe K, Enomoto H, Toyama
Y, Akiba T and Yanaga K: Normalization of serum p53 antibody levels
in patients after curative resection for colorectal cancer.
Anticancer Res. 33:2221–2225. 2013.PubMed/NCBI
|
|
20
|
Nozoe T, Yasuda M, Honda M, Inutsuka S and
Korenaga D: Clinicopathologic significance in serum presence of
anti-p53 antibody in patients with colorectal carcinoma.
Hepatogastroenterology. 54:1422–1425. 2007.PubMed/NCBI
|
|
21
|
Nakajima K, Suzuki T, Shimada H, Hayashi
H, Takeda A and Ochiai T: Detection of preoperative serum anti-p53
antibodies in gastric cancer. Tumour Biol. 20:147–152. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimada H, Nakajima K, Ochiai T, Koide Y,
Okazumi SI, Matsubara H, Takeda A, Miyazawa Y, Arima M and Isono K:
Detection of serum p53 antibodies in patients with esophageal
squamous cell carcinoma: Correlation with clinicopathologic
features and tumor markers. Oncol Rep. 5:871–874. 1998.PubMed/NCBI
|
|
23
|
Kressner U, Glimelius B, Bergström R,
Påhlman L, Larsson A and Lindmark G: Increased serum p53 antibody
levels indicate poor prognosis in patients with colorectal cancer.
Br J Cancer. 77:1848–1851. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morikawa T, Kuchiba A, Liao X, Imamura Y,
Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS
and Ogino S: Tumor TP53 expression status, body mass index and
prognosis in colorectal cancer. Int J Cancer. 131:1169–1178. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Russo A, Bazan V, Iacopetta B, Kerr D,
Soussi T and Gebbia N: TP53-CRC Collaborative Study Group: The TP53
colorectal cancer international collaborative study on the
prognostic and predictive significance of p53 mutation: Influence
of tumor site, type of mutation and adjuvant treatment. J Clin
Oncol. 23:7518–7528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Munro AJ, Lain S and Lane DP: P53
abnormalities and outcomes in colorectal cancer: A systematic
review. Br J Cancer. 92:434–444. 2005.PubMed/NCBI
|
